Vertex Pharmaceuticals Exceeds Profit Estimates as Sales of New Cystic Fibrosis Drug Surge
Vertex Pharmaceuticals exceeded Wall Street's adjusted profit estimates for Q1 2026, driven by a significant increase in sales from its new cystic fibrosis drug Alyftrek. The once-daily therapy generated $424.4 million in revenue during the quarter—a 687% year-over-year surge—following its December 2024 approval.
Tickers: $VRTX
Topics: cystic fibrosis drug sales growth gene therapy non-opioid pain treatment